Back to top

Image: Bigstock

Agios Pharmaceuticals, Inc.

Read MoreHide Full Article

Agios’ leukemia drug Tibsovo was approved by the FDA for treating AML. The approval came one month earlier before the action date of Aug 21, 2018 which is a huge boost for the company as it represents immense commercial potential in the AML market. The company’s progress with the pipeline candidates, AG-348 and AG-881, has been quite impressive too. The company, initiated phase I study for AG-270 and also initiated pivotal program for AG-348 in PK deficiency. We are also optimistic about Agios' collaboration with Celgene as it provides Agios with regular funds. However, Agios depends heavily on partner Celgene for revenues which is a concern. Stiff competition is another matter of concern for the company. Shares have outperformed the industry so far this year. Loss estimates has narrowed ahead of the company’s Q2 earnings release. Agios has a negative record of earnings surprises in recent quarters.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Agios Pharmaceuticals, Inc. (AGIO) - free report >>

Published in